

# Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/ICD5EBDEC27BEN.html>

Date: August 2019

Pages: 76

Price: US\$ 3,500.00 (Single User License)

ID: ICD5EBDEC27BEN

## Abstracts

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H2 2019

### SUMMARY

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 20 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3 and 7 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Acute Myelocytic Leukemia (AML, Acute

Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Myelodysplastic Syndrome, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer, Hematological Tumor, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Non-Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), T-Cell Lymphomas and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)

The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects

The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Overview

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Companies Involved in Therapeutics Development

AbbVie Inc

Aileron Therapeutics Inc

Amgen Inc

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

Circle Pharma Inc

Complix NV

InteRNA Technologies BV

Les Laboratoires Servier SAS

Pfizer Inc

X-Rx Inc

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Drug Profiles

AMG-176 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-397 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-5991 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-1B3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-63845 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-64315 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL1 for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MCL1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit MCL1 and BCL1 for Solid Tumors and Liquid Tumors -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMI-77 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Dormant Products

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Product Development Milestones

Featured News & Press Releases

Mar 25, 2019: InteRNA appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

Feb 28, 2019: Amgen highlights progress of innovative early oncology pipeline including AMG-176 new data at AACR 2019

Nov 27, 2018: AstraZeneca to present on its multiple myeloma drug candidate AZD5991 at 2018 American Society of Hematology Annual Meeting

Oct 12, 2018: New model mimics human tumours for accurate testing of cancer drugs

Oct 01, 2018: InteRNA presents expanded preclinical proof-of-concept data on lead oncology development candidate INT-1B3 at the 14th Annual OTS Meeting

Apr 18, 2018: InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

Apr 09, 2018: Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018

Dec 14, 2017: Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies against intracellular cancer targets

Aug 03, 2017: Targeting Cancers Achilles Heel To Improve Breast Cancer Treatment

Mar 31, 2017: Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Oct 20, 2016: New compound shows promise in treating multiple human cancers

Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy

Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies

Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer

Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by AbbVie Inc, H2 2019  
Pipeline by Aileron Therapeutics Inc, H2 2019  
Pipeline by Amgen Inc, H2 2019  
Pipeline by AstraZeneca Plc, H2 2019  
Pipeline by Boehringer Ingelheim International GmbH, H2 2019  
Pipeline by Canget BioTekpharma LLC, H2 2019  
Pipeline by Circle Pharma Inc, H2 2019  
Pipeline by Complix NV, H2 2019  
Pipeline by InterRNA Technologies BV, H2 2019  
Pipeline by Les Laboratoires Servier SAS, H2 2019  
Pipeline by Pfizer Inc, H2 2019  
Pipeline by X-Rx Inc, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

AbbVie Inc

Aileron Therapeutics Inc

Amgen Inc

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

Circle Pharma Inc

Complix NV

InteRNA Technologies BV

Les Laboratoires Servier SAS

Pfizer Inc

X-Rx Inc

## I would like to order

Product name: Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/ICD5EBDEC27BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ICD5EBDEC27BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970